ADL Amdl,

TUSTIN, Calif., Nov. 28 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today it intends to gain significant market share in the rapidly expanding Chinese pharmaceutical market through recent licensing agreements and product acquisitions by its China subsidiary Jade Pharmaceutical from Chinese drug distributor and manufacturer JMB. With the transfer of production licenses and manufacturing registration numbers, Jade Pharmaceutical will focus on selling into the China pharmaceutical products market with four new drugs (Marine and Sodium Chloride Injection, Lomefloxacin Aspartate Injection, Lysine Hydrochloride and Glucose Injection, Omeprazole Sodium for Injection) and two antibiotic medicines, Roxithromycin and Levofloxacin. According to IMS Health, pharmaceutical product sales in China grew 20.4 percent to $11.7 billion in 2005, representing the third consecutive year the market has achieved more than 20 percent growth. China is projected to become the world's seventh largest pharmaceutical market by 2009. The market for antibiotic products (including Roxithromycin and Levofloxacin) exceeded (US) $4.8 billion globally in 2003 with a continuing estimated growth rate of 20 percent annually. "The new licensing agreements and product acquisitions bolster Jade's existing pharmaceutical and consumer product offerings. We look forward to serving the rapidly expanding Chinese pharmaceutical market while continuing to develop and acquire compelling products," said Gary Dreher, AMDL CEO. Jade Pharmaceutical will manufacture products at the Jiangxi Jade Biochemistry Ltd. facility in the South China City of Shargro in the Jiangxi Province of China. At present, these products will only be sold in the People's Republic of China. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. AMDL, Inc. Gary L. Dreher President & CEO Contact (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright